옵션 체인은 다양한 행사가격과 만기일에 대한 View Inc Warrants (08/03/2026)의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 View Inc Warrants (08/03/2026)에 대한 시장 심리를 평가합니다..

View Inc Warrants (08/03/2026) (OTC:VIWWQ) 주식, 옵션 체인

View Inc Warrants (08/03/2026)

Roth MKM analyst Sean McGowan maintains Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) with a Buy and lowers the price target from $40 to $38.

News

Price Target

Analyst Ratings

CELH

Roth MKM Maintains Buy on Celsius Holdings, Lowers Price Target to $38

WIIM

ENVX

Enovix shares are trading lower Monday after the company announced the departure of its CFO.

BTIG analyst Gregory Lewis maintains Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) with a Buy and raises the price target from $170 to $210.

GTLS

BTIG Maintains Buy on Chart Industries, Raises Price Target to $210

Macro Economic Events

Politics

Economics

General

President-Elect Donald Trump Says "Will Keep Promise To Pass Historic Tax Cuts"

JP Morgan analyst John Royall maintains Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) with a Overweight and lowers the price target from $130 to $125.

JP Morgan Maintains Overweight on Exxon Mobil, Lowers Price Target to $125

BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) shares are trading higher Monday after the company announced an acquisition agreement for its <a href="https://www.benzinga.com/pressreleases/24/12/ac42508111/arctic-wolf-and-blackberry-announce-acquisition-agreement-for-cylance">endpoint security assets</a>. 
What Happened: BlackBerry and Arctic Wolf entered into a definitive agreement for Arctic Wolf to acquire BlackBerry&#8217;s Cylance endpoint security assets. Cylance&#8217;s AI-based endpoint protection is trusted by thousands of organizations around the world.
Under the terms of the agreement, BlackBerry will sell the Cylance assets to Arctic Wolf for $160 million in cash and approximately 5.5 million common shares of Arctic Wolf. The company expects to receive approximately $80 million in cash at closing and approximately $40 million in cash one year later.
&#8220;We see this transaction as a win-win for our shareholders and all other stakeholders. Our customers will realize the benefits of continuity of service and the expertise that a global cybersecurity leader like Arctic Wolf provides,&#8221; said John Giamatteo, CEO of BlackBerry. 
&#8220;As Arctic Wolf leverages its scale to build upon and grow the Cylance business, BlackBerry will benefit as a reseller of the portfolio to our large government customers and as a shareholder of the company.&#8221;
See Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/24/12/42508800/frances-credit-rating-downgrade-sparks-market-unease-public-finances-will-be-materially-weaker">France&#8217;s Credit Rating Downgrade Sparks Market Unease: &#8216;Public Finances Will Be Materially Weaker&#8217;</a>
The proposed transaction is expected to close in BlackBerry&#8217;s fiscal fourth quarter. The company said there will not be any impact to BlackBerry&#8217;s secure communications portfolio of businesses.
BlackBerry is due to report financial results for its fiscal third quarter after the market close on Thursday. Analysts expect the company to report a loss of 1 cent per share and revenue of $150.76 million, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
BB Price Action: <a href="http://benzinga.com/quote/bb">BlackBerry shares</a> were up 16.5% at $3.13 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of BlackBerry.

Movers

BlackBerry Stock Is Rising Monday: What's Going On?

Investors with a lot of money to spend have taken a bullish stance on Capri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CPRI, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Capri Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 40%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $42,665, and 9, calls, for a total amount of $652,405.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $17.5 to $25.0 for Capri Holdings over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Capri Holdings's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Capri Holdings's whale trades within a strike price range from $17.5 to $25.0 in the last 30 days. 
<h3>Capri Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734366630_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPRI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$1.0</td>
<td>$0.85</td>
<td>$0.95</td>
<td>$22.50</td>
<td>$190.0K</td>
<td>58</td>
<td>2.0K</td>
</tr>
<tr>
<td>CPRI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.4</td>
<td>$1.25</td>
<td>$1.25</td>
<td>$21.50</td>
<td>$136.2K</td>
<td>3.2K</td>
<td>2.8K</td>
</tr>
<tr>
<td>CPRI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$21.50</td>
<td>$94.7K</td>
<td>3.2K</td>
<td>1.2K</td>
</tr>
<tr>
<td>CPRI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$3.2</td>
<td>$3.0</td>
<td>$3.03</td>
<td>$22.50</td>
<td>$75.7K</td>
<td>3.2K</td>
<td>250</td>
</tr>
<tr>
<td>CPRI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.8</td>
<td>$4.6</td>
<td>$4.79</td>
<td>$25.00</td>
<td>$47.4K</td>
<td>240</td>
<td>106</td>
</tr>
</tbody>
</table>

<h3>About Capri Holdings</h3>
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
<h3>Present Market Standing of Capri Holdings</h3>
<ul>
<li>With a trading volume of 2,836,563, the price of CPRI is up by 7.54%, reaching $22.97.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 52 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Capri Holdings</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $25.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a positive move, an analyst from Guggenheim has upgraded their rating to Buy and adjusted the price target to $30. 
&#x2A; In a cautious move, an analyst from Barclays downgraded its rating to Equal-Weight, setting a price target of $21. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Capri Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

CPRI

Decoding Capri Holdings's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bullish stance on Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LRCX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Lam Research.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 46%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $120,250, and 10 are calls, for a total amount of $717,135.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $88.0 for Lam Research over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Lam Research's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Lam Research's substantial trades, within a strike price spectrum from $60.0 to $88.0 over the preceding 30 days.
<h3>Lam Research Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734366624_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.5</td>
<td>$4.35</td>
<td>$4.45</td>
<td>$76.00</td>
<td>$222.5K</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.6</td>
<td>$4.45</td>
<td>$4.45</td>
<td>$76.00</td>
<td>$167.7K</td>
<td>2.2K</td>
<td>502</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$16.8</td>
<td>$16.25</td>
<td>$16.8</td>
<td>$60.00</td>
<td>$84.0K</td>
<td>80</td>
<td>50</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$13.4</td>
<td>$13.3</td>
<td>$13.3</td>
<td>$88.00</td>
<td>$46.5K</td>
<td>964</td>
<td>43</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.73</td>
<td>$0.69</td>
<td>$0.7</td>
<td>$80.00</td>
<td>$45.0K</td>
<td>7.7K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About Lam Research</h3>
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
After a thorough review of the options trading surrounding Lam Research, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Lam Research Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,214,827, with LRCX's price down by 0.0%, positioned at $76.26.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 37 days.</li>
</ul>
<h3>Expert Opinions on Lam Research</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $82.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Lam Research, targeting a price of $78. 
&#x2A; Consistent in their evaluation, an analyst from Bernstein keeps a Market Perform rating on Lam Research with a target price of $85. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Lam Research, maintaining a target price of $83. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Lam Research with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

LRCX

Check Out What Whales Are Doing With LRCX

Financial giants have made a conspicuous bearish move on Adobe. Our analysis of options history for Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) revealed 45 unusual trades.
Delving into the details, we found 31% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 36 were puts, with a value of $1,833,565, and 9 were calls, valued at $518,612.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $230.0 to $590.0 for Adobe over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Adobe options trades today is 708.37 with a total volume of 9,660.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Adobe's big money trades within a strike price range of $230.0 to $590.0 over the last 30 days.
<h3>Adobe Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734366618_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.27</td>
<td>$1.23</td>
<td>$1.23</td>
<td>$450.00</td>
<td>$234.0K</td>
<td>2.7K</td>
<td>2.8K</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$266.95</td>
<td>$257.0</td>
<td>$262.98</td>
<td>$230.00</td>
<td>$210.3K</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$18.65</td>
<td>$16.35</td>
<td>$16.35</td>
<td>$480.00</td>
<td>$163.5K</td>
<td>2.1K</td>
<td>0</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$24.85</td>
<td>$24.1</td>
<td>$24.72</td>
<td>$350.00</td>
<td>$94.2K</td>
<td>175</td>
<td>42</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$78.55</td>
<td>$76.5</td>
<td>$76.75</td>
<td>$540.00</td>
<td>$92.1K</td>
<td>404</td>
<td>12</td>
</tr>
</tbody>
</table>

<h3>About Adobe</h3>
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
<h3>Present Market Standing of Adobe</h3>
<ul>
<li>Currently trading with a volume of 2,083,910, the ADBE's price is up by 0.68%, now at $468.84. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 87 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Adobe with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ADBE

Adobe's Options: A Look at What the Big Money is Thinking

Jim Carrey Returns To Acting, Saying, &#8216;I Bought A Lot Of Stuff,&#8217; Joining A Growing List Of Retired Actors Returning For Financial Reasons
For <a href="https://www.benzinga.com/real-estate/24/11/41982378/trumps-win-has-celebrities-saying-goodbye-america-see-where-theyre-going">Hollywood celebrities</a>, retirement does not necessarily mean ending one&#8217;s career. Jim Carrey recently disclosed that, as formerly one of the highest-paid actors in the world, the majority of his motivation for returning to acting was financial.&nbsp;
After Sonic the Hedgehog 2, the 62-year-old actor, who starred in classic films like The Truman Show and Liar Liar, declared in 2022 that he was retiring. At the time, he said he would only return for a special project that felt like it was written &#8220;in gold ink.&#8221;
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Fast-forward less than two years, Carrey is back in Sonic the Hedgehog 3, playing Dr. Robotnik and his character&#8217;s grandfather. At the film&#8217;s London premiere, Carrey admitted, &#8220;I came back to this universe because I get to play a genius, which is a bit of a stretch. And it's just … I bought a lot of stuff and I need the money, frankly.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Jim Carrey explains his return to playing Dr. Robotnik in &quot;Sonic the Hedgehog 3&quot;: &quot;I bought a lot of stuff and I need the money, frankly.&quot; <a href="https://t.co/pIFJPuAyRM">pic.twitter.com/pIFJPuAyRM</a>
&mdash; AP Entertainment (@APEntertainment) <a href="https://twitter.com/APEntertainment/status/1866579281045811233?ref_src=twsrc%5Etfw">December 10, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
While he joked about his financial situation, Carrey said the franchise's heartfelt story drew him back. With the first two Sonic movies grossing a combined $725 million globally, it's clear this isn't just a passion project – it's a smart paycheck.
See Also: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Carrey isn't alone in returning to work to help balance the books. Hugh Grant, who plays an Oompa Loompa in the 2023 Wonka film, also admitted financial motivation. &#8220;I slightly hate [making films], but I have many children and need money,&#8221; Grant said at a press conference. The 63-year-old actor, who has five kids, shared that he found motion-capture work for the role &#8220;very uncomfortable&#8221; but took the part anyway.
Both Carrey and Grant were major stars at their peaks. During his heyday, Carrey commanded $20 million per movie, while Grant became a romantic-comedy legend. But big incomes don't always last forever. Carrey, for example, has been trying to sell his lavish Los Angeles mansion for nearly two years, cutting the price from $28.9 million to $19 million in September. He bought the property in 1994 for $3.8 million, but despite the discounts, it's clear he's looking for a significant profit.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a>
For Grant, who has once said he &#8220;pretty much hated any other film&#8221; he's ever been in, acting seems like a reluctant necessity to fund his large family. Similarly, despite his fortune, Carrey seems to be making choices to keep his financial footing steady.
These honest admissions show a growing trend among stars who find <a href="https://www.benzinga.com/money/retirement-planning-guide">retirement</a> less permanent than they thought. Whether it's a return for the love of storytelling, financial security or both, Carrey, Grant and others, remind us that even Hollywood royalty can face the reality of balancing the books – albeit with seven-figure paychecks.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
</ul>

'I Bought A Lot Of Stuff,' Jim Carrey Admits, Joining Other Stars Returning To Acting Due To Money Woes After Retirement

TD Cowen analyst Max Rakhlenko maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Buy and raises the price target from $3450 to $3800.

TD Cowen Maintains Buy on AutoZone, Raises Price Target to $3800

Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) has outperformed the market over the past 5 years by 2.69% on an annualized basis producing an average annual return of 16.29%. Currently, Ciena has a market capitalization of $12.96 billion. 
Buying $100 In CIEN: If an investor had bought $100 of CIEN stock 5 years ago, it would be worth $217.10 today based on a price of $90.16 for CIEN at the time of writing.
<h3>Ciena's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734366607_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CIEN

$100 Invested In Ciena 5 Years Ago Would Be Worth This Much Today

Lake Street analyst Thomas Flaten maintains Checkpoint Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CKPT#NASDAQ">CKPT</a>) with a Buy and raises the price target from $4 to $7.

CKPT

Lake Street Maintains Buy on Checkpoint Therapeutics, Raises Price Target to $7

Aehr Test Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) stock is trading higher on Monday after the company announced that it secured a $10 million order for artificial intelligence semiconductor testing <a href="https://www.benzinga.com//node/42505803">equipment</a>.
The Details: The $10 million order includes multiple high-power FOX-XP wafer-level test and burn-in systems, as well as several sets of Aehr&#8217;s proprietary WaferPak Contactors.
This technology allows customers to perform production wafer-level burn-in for AI processors. It helps reduce costs and improve yields by identifying early life failures during production while the devices are still in wafer form, prior to assembly into modules or systems.
&#8220;This marks a technology and commercial breakthrough for Aehr as it significantly expands the market opportunities for our FOX-XP wafer level test and burn-in systems,&#8221; said Gayn Erickson, CEO of Aehr.
The first FOX-XP wafter system is scheduled to ship immediately, with the remaining systems and initial WaferPaks set to be delivered within 90 days.
Related Link: <a href="https://www.benzinga.com/insights/news/24/12/42508964/heres-how-much-you-would-have-made-owning-applied-mat-stock-in-the-last-15-years">Here&#8217;s How Much You Would Have Made Owning Applied Mat Stock In The Last 15 Years</a>
AEHR Price Action: At the time of publication, Aehr stock is trading 20.9% higher at $13.94 , according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 5475664 from Pixabay.

AEHR

What's Going On With Aehr Test Systems Shares Monday?

JP Morgan analyst Domingos Falavina maintains PagSeguro Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAGS#NYSE">PAGS</a>) with a Neutral and lowers the price target from $16 to $11.

PAGS

JP Morgan Maintains Neutral on PagSeguro Digital, Lowers Price Target to $11

TD Cowen analyst Jonna Kim initiates coverage on Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) with a Hold rating and announces Price Target of $4.3.

Initiation

WALD

TD Cowen Initiates Coverage On Waldencast with Hold Rating, Announces Price Target of $4.3

Lake Street analyst Ben Klieve maintains Chefs' Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) with a Buy and raises the price target from $48 to $60.

CHEF

Lake Street Maintains Buy on Chefs' Warehouse, Raises Price Target to $60

President-Elect Trump Says Proposals Being Considered Include Federal Workers Who Don't Return To The Office Should Be Dismissed

Date Issued: December 16, 2024
The U.S. Food and Drug Administration (FDA) is alerting patients, caregivers, and health care providers about the potential need for early device replacement of Boston Scientific Corporation (Boston Scientific) Accolade pacemaker devices, which includes the Accolade, Proponent, Essentio, and Altrua 2 Standard Life (SL) and Extended Life (EL) pacemakers, and the Visionist and Valitude cardiac resynchronization therapy pacemakers.
Boston Scientific announced a <a href="https://www.bostonscientific.com/content/dam/bostonscientific/quality/documents/Recent%20Product%20Advisories/2024_Dec_BSC_ACCOLADE_HighImpedance_PhysLtr_FINAL7_US.pdf">recall</a> for a subset of Accolade pacemaker devices with an increased risk to permanently enter Safety Mode, which has limited functionality and has been associated with the pacemaker being unable to properly regulate the heart's rhythm and rate in some patients. A device that enters Safety Mode should be replaced. The increased risk of permanently entering Safety Mode in this subset of Accolade pacemaker devices is due to the battery underpowering the system because of a manufacturing issue. &nbsp;
While the recall by Boston Scientific identifies a subset of Accolade pacemaker devices with increased risk of entering Safety Mode, the FDA is working with the manufacturer to evaluate the potential risk of this issue in all Accolade pacemaker devices and identify additional mitigation strategies as needed.&nbsp;
The FDA is issuing this communication to raise awareness of the manufacturer's recall notice, the FDA's ongoing evaluation with the manufacturer of the issue, and the FDA's current recommendations.
<h2>Recommendations for Patients and Caregivers</h2>
<ul>
<li>Continue to work with your health care provider to monitor your Accolade pacemaker device, either remotely or during your existing in-office follow-up schedule.&nbsp;
<ul>
<li>Discuss with your health care provider if you are a candidate for remote monitoring. Remote monitoring enables your provider to receive regular updates, including a Safety Mode alert, from your device.&nbsp;</li>
<li>If not a candidate for remote monitoring, discuss an in-office monitoring schedule with your health care provider to help ensure that your device is functioning properly.&nbsp;</li>
<li>If monitoring indicates that your device entered Safety Mode, discuss a plan with your health care provider for surgery to replace the pacemaker.&nbsp;</li>
</ul>
</li>
<li>Discuss your current pacing needs and potential risk of your device entering Safety Mode with your health care provider.
<ul>
<li>If you are determined to be at high risk of harm &nbsp;if your device entered Safety Mode based on your pacing needs, your health care provider may contact you about replacement of your device.</li>
</ul>
</li>
<li>Consult with your health care provider if you have new or worsening symptoms such as lightheadedness or loss of consciousness, or questions about your device potentially entering Safety Mode.&nbsp;</li>
<li><a href="http://www.fda.gov/medical-devices/safety-communications/accolade-pacemaker-devices-boston-scientific-and-potential-need-early-device-replacement-fda-safety#reporting">Report any problems</a> with your Accolade pacemaker device to the FDA.</li>
</ul>
<h2>Recommendations for Health Care Providers</h2>
<ul>
<li>Review the <a href="https://www.bostonscientific.com/content/dam/bostonscientific/quality/documents/Recent%20Product%20Advisories/2024_Dec_BSC_ACCOLADE_HighImpedance_PhysLtr_FINAL7_US.pdf">recall notice</a> from Boston Scientific for a subset of Accolade pacemaker devices with an increased risk to permanently enter Safety Mode due to the battery underpowering the system because of a manufacturing issue with the battery cathode. The recall notice includes the following important information:
<ul>
<li>Description of the battery problem and clinical impact of Safety Mode,</li>
<li>Recommended actions for individual patient evaluation, device replacement, and follow-up intervals, and</li>
<li>Model numbers and Unique Device Identifier (UDI) information.&nbsp;</li>
</ul>
</li>
<li>Be aware that the FDA is working with the manufacturer to evaluate the potential risk of this issue in all Accolade pacemaker devices.
<ul>
<li>Consider the potential need for early device replacement and a patient's specific reliance on their pacemaker when making treatment recommendations.</li>
<li>Discuss the benefit and risks of all available treatment options with your patients.&nbsp;</li>
<li>Remain alert for further updates and recommendations from the FDA and the manufacturer.</li>
<li>While the FDA's evaluation is ongoing, health care providers should:
<ul>
<li>Monitor patients with Accolade pacemaker devices through remote or in-office visits for red box alerts indicating that a patient's device is in Safety Mode, or symptoms indicating device performance issues, such as lightheadedness or loss of consciousness. General prophylactic device replacement is not recommended.&nbsp;</li>
<li>If monitoring indicates that the device has entered Safety Mode, schedule surgery for a replacement pacemaker. Timely replacement is recommended to avoid risks associated with time spent in Safety Mode.</li>
</ul>
</li>
</ul>
</li>
<li><a href="http://www.fda.gov/medical-devices/safety-communications/accolade-pacemaker-devices-boston-scientific-and-potential-need-early-device-replacement-fda-safety#reporting">Report any problems</a> your patients experience with Accolade pacemaker devices to the FDA.</li>
</ul>
<h2>Device Description</h2>
The Accolade devices are a family of pacemakers and cardiac resynchronization therapy pacemakers that are implanted to treat abnormal heartbeat (arrhythmia) and moderate to severe heart failure.
<h2>Potential Need for Early Device Replacement of Accolade Pacemaker Devices</h2>
The FDA is aware of a manufacturing issue with the cathode of some Accolade pacemaker device batteries that may lead to underpowering the device system and may cause the pacemakers to permanently enter Safety Mode, which requires pacemaker replacement.
Pacemakers that enter Safety Mode require replacement because Safety Mode offers limited functioning of the pacemaker and has been associated with the pacemaker being unable to properly regulate the heart's rhythm and rate in some patients. Safety Mode can only be identified through office visits or through remote monitoring using the Boston Scientific Latitude Communicator system.
The manufacturer plans to implement updated manufacturing work instructions for the process used to make the cathodes for Accolade product batteries. In addition, the manufacturer is developing a software update to detect battery health in all Accolade pacemaker devices.
<h2>FDA Actions</h2>
The FDA will continue working with Boston Scientific to help ensure that patients, caregivers, and providers are aware of the issue, evaluate information to better understand the issue, and to identify additional mitigation strategies as needed. &nbsp; &nbsp;
The FDA will continue to monitor information about device performance including medical device reports.
The FDA will keep the public informed as new information becomes available.

FDA Alerting About Potential Need For Early Device Replacement Of Boston Scientific Accolade Pacemaker Devices; Boston Scientific Announced Recall For Subset Of Accolade Pacemaker Devices With Increased Risk To Permanently Enter Safety Mode

JP Morgan analyst Yuri Fernandes maintains StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) with a Overweight and lowers the price target from $21 to $15.

Comments

View Inc Warrants (08/03/2026)

View Inc Warrants (08/03/2026) (VIWWQ) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌